F A Greco

Summary

Affiliation: Sarah Cannon Cancer Center
Country: USA

Publications

  1. request reprint
    Greco F, Burris H, Erland J, Gray J, Kalman L, Schreeder M, et al. Carcinoma of unknown primary site. Cancer. 2000;89:2655-60 pubmed
    ..Although the regimen reported in the current study can become an attractive option for many patients with carcinoma of unknown primary site, there remains a need for further clinical trials. ..
  2. Greco F, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol. 2009;36:65-74 pubmed publisher
    ..Improvements in diagnostic pathology and molecular characterization of these carcinomas are likely to soon help select more appropriate and tailored therapies for many of these patients. ..
  3. Greco F, Erlander M. Molecular classification of cancers of unknown primary site. Mol Diagn Ther. 2009;13:367-73 pubmed publisher
    ..Several clinical studies are in progress or planned to test this concept. ..
  4. Greco F, Lennington W, Spigel D, Hainsworth J. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay. Mol Diagn Ther. 2015;19:91-7 pubmed publisher
    ..Earlier use of MCCA will expedite diagnosis and direct appropriate first-line therapy, which is potentially curative for several of these tumor types. ..
  5. Spigel D, Hainsworth J, Shipley D, Mekhail T, Zubkus J, Waterhouse D, et al. Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium. Lung Cancer. 2018;117:38-43 pubmed publisher
    ..Severe myelosuppression was common with this regimen, in spite of prophylactic pegfilgrastim. These results are consistent with those of other trials in showing no role for amrubicin in the first-line treatment of SCLC. ..
  6. Greco F, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, et al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol. 2012;23:298-304 pubmed publisher
    ..The longer-term objective is to understand the biology of highly metastatic disease, leading to the development of future global therapeutic programs. Current clinical studies, such as CUP-ONE, will address some of these issues. ..
  7. request reprint
    Greco F, Burris H, Litchy S, Barton J, Bradof J, Richards P, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002;20:1651-6 pubmed
    ..To evaluate the efficacy and toxicity of the novel chemotherapy combination that includes gemcitabine, carboplatin, and paclitaxel in the treatment of patients with carcinoma of unknown primary site...
  8. request reprint
    Greco F, Hainsworth J. Emerging role of topotecan in first-line therapy of small-cell lung cancer. Clin Lung Cancer. 2003;4:279-87 pubmed
  9. Spigel D, Rubin M, Gian V, Shipley D, Burris H, Kosloff R, et al. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). Lung Cancer. 2017;113:79-84 pubmed publisher
    ..Both regimens tested had limited efficacy, consistent with results from other studies. ClinicalTrials.gov ID:NCT00609804. ..